RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing
FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.
The RoosterVial™-XF line of products are cryopreserved human bone marrow-derived MSCs, designed to serve as manufacturing starting materials, and are offered in various high volume formats, including 1, 10 and 50 million cells per vial. These first-in-class xeno-free hMSC cell bank product offerings expand RoosterBio’s development grade product portfolio and are complementary to RoosterBio’s other industry-leading stem cell bioprocessing systems.
First generation cell therapies traditionally relied on bovine serum in their manufacturing processes. As the industry evolves, the market is seeking more sophisticated XF tools and processes. RoosterBio is bringing these XF design requirements into its biomanufacturing product configurations with the goal of reducing regulatory burden and enhancing the long-term safety profile of cell-based therapies. By incorporating XF starting materials at early stages of product development, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs.
Jon A Rowley, RoosterBio’s Chief Technology Officer, states, “We’re very excited to launch this product line, particularly as it relates to advancing the RM industry. Last year, we launched XF bioprocess media, and now we’re introducing the XF cell banks to complete the system. Together, these products give our customers all the tools they need to develop their RM products, whether they are developing cellular therapies, cell-based gene therapies, hMSC-derived exosomes, or bioprinted engineered tissues.”
The release of these products reinforces RoosterBio’s ongoing mission to support the acceleration of the Regenerative Medicine industry.
To learn more about RoosterBio Inc., please contact us at +1 301-360-3545 or [email protected]
About RoosterBio, Inc.
RoosterBio, Inc. is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio and adult stem cells, please visit http://www.roosterbio.com, follow on twitter (@RoosterBio), or read our corporate blog (http://www.roosterbio.blogspot.com).
Original PR available at: http://www.prweb.com/releases/2017/05/prweb14302156.htm